Every biosimilar we add to our portfolio provides more patients in more countries with the treatment they need.
We are committed to continuing to
invest in biosimilars.
We offer one of the industry's largest and
most diverse global biosimilars franchises
focused on the areas of oncology,
immunology, endocrinology, ophthalmology
At present, Health Canada has approved 27 biosimilars for use in Canada, within the product classes of human growth hormone, granulocyte colony-stimulating factor (G-CSF), insulin, monoclonal antibodies and tumour necrosis factor (TNF)-inhibitor.1
Biosimilars play an important role in our commitment by offering additional
therapeutic options to more expensive biologics.
Increasing uptake of biosimilars in Canada is projected to generate potential savings of as high as CA $447 million by 2023.2